Virginia Board of Medicine Practitioner Information

Home Icon Home

Search Icon Search

Disclaimer Icon Disclaimers

Links Icon Links

Glossary Icon Glossary

Help Icon Questions


Printer Friendly Version Printer Icon
 

Jeanny B. Aragon-Ching, MD

LICENSE # 0101258348
  https://www.inova.org/Physician_Directory/Jeanny-B-Aragon-Ching-MD/824961/
Issue Date: 5/21/2015
Expiration Date: 10/31/2024
Status: Current Active


General InformationEducationCertifications & Practice AreaInsuranceHonors & AwardsAcademic Appointments & PublicationsProceedings, Actions & ConvictionsPaid Claims
Unless otherwise indicated, this information has been self-reported and has not been verified by the Board of Medicine.


Academic Appointments
Last Updated 9/17/2022
George Washington University School Of Medicine And Health Sciences - Washington DC
Rank: Assistant Professor
Years: 2008-2014

George Washington University School Of Medicine And Health Sciences - Washington DC
Rank: Associate Professor
Years: 2014-2015

Virginia Commonwealth University School Of Medicine-INOVA Campus - Falls Church VA
Rank: Associate Professor
Years: 2015 - 2020

University Of Virginia School Of Medicine - Charlottesville VA
Rank: Associate Professor
Years: 2020 - Present

Academic Appointments - Non-US
Last Updated 9/17/2022
None Reported
Publications
(up to ten in the last five years)
Last Updated 9/17/2022
Unravelling the role of denosumab in prostate cancer
Lancet
Volume: 377
Date: 03 2011
www.thelancet.com/pdfs/journals/lancet/PIIS0140-6736(11)60100-1.pdf

Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms
Prostate Cancer
Volume: 2013
Date: 08 2013
www.ncbi.nlm.nih.gov/pmc/articles/PMC3771418/

Phase II study of satraplatin and prednisone in patients with metastatic castration-resistant prostate cancer: a pharmacogenetic assessment of outcome and toxicity.
Clinical Genitourinary Cancer
Volume: 11
Date: 09 2013
www.ncbi.nlm.nih.gov/pmc/articles/PMC3758779/

Use of denosumab for renal cell carcinoma-associated malignant hypercalcemia: a case report and review of the literature.
Clinical Genitourinary Cancer
Volume: 11
Date: 12 2013
www.clinical-genitourinary-cancer.com/article/S1558-7673(13)00158-4/abstract

American Cancer Society prostate cancer survivorship care guidelines.
CA Cancer J Clin
Volume: 64
Date: 07 2014
onlinelibrary.wiley.com/doi/10.3322/caac.21234/pdf

Advances in systemic therapies for metastatic castration-resistant prostate cancer
Future Oncology
Volume: 10 (14)
Date: 11 2014
www.futuremedicine.com/doi/abs/10.2217/fon.14.128?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rf

Neoadjuvant chemotherapy for muscle-invasive bladder cancer: are we asking the right questions?
J Clin Oncol
Volume: 32
Date: 12 2014
jco.ascopubs.org/content/32/36/4169.long

Circulating Tumor Cells in Biochemical Recurrence of Prostate Cancer
Clinical Genitourinary Cancer
Epub ahead of print
Date: 04 2015
www.clinical-genitourinary-cancer.com/article/S1558-7673(15)00075-0/abstract

Clinical Cancer Advances 2017: Annual Report on Progress Against Cancer From the American Society of Clinical Oncology.
J Clin Oncol
Volume: 35
Date: 04 2017
ascopubs.org/doi/abs/10.1200/JCO.2016.71.5292?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_da

Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
New England Journal of Medicine
Date: 09 2020
https://www.nejm.org/doi/full/10.1056/NEJMoa2002788